417 related articles for article (PubMed ID: 25468648)
1. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient.
Fox JE; Volpe L; Bullaro J; Kakkis ED; Sly WS
Mol Genet Metab; 2015 Feb; 114(2):203-8. PubMed ID: 25468648
[TBL] [Abstract][Full Text] [Related]
2. Vestronidase alfa: Recombinant human β-glucuronidase as an enzyme replacement therapy for MPS VII.
Cadaoas J; Boyle G; Jungles S; Cullen S; Vellard M; Grubb JH; Jurecka A; Sly W; Kakkis E
Mol Genet Metab; 2020 May; 130(1):65-76. PubMed ID: 32192868
[TBL] [Abstract][Full Text] [Related]
3. The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII.
Wang RY; da Silva Franco JF; López-Valdez J; Martins E; Sutton VR; Whitley CB; Zhang L; Cimms T; Marsden D; Jurecka A; Harmatz P
Mol Genet Metab; 2020 Mar; 129(3):219-227. PubMed ID: 32063397
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII.
Lau HA; Viskochil D; Tanpaiboon P; Lopez AG; Martins E; Taylor J; Malkus B; Zhang L; Jurecka A; Marsden D
Mol Genet Metab; 2022 May; 136(1):28-37. PubMed ID: 35331634
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials.
Qi Y; McKeever K; Taylor J; Haller C; Song W; Jones SA; Shi J
Clin Pharmacokinet; 2019 May; 58(5):673-683. PubMed ID: 30467742
[TBL] [Abstract][Full Text] [Related]
6. Disease characteristics, effectiveness, and safety of vestronidase alfa for the treatment of patients with mucopolysaccharidosis VII in a novel, longitudinal, multicenter disease monitoring program.
Giugliani R; Gonzalez-Meneses A; Scarpa M; Burton B; Wang R; Martins E; Oussoren E; Hennermann JB; Chabrol B; Grant CL; Sun A; Durand C; Hetzer J; Malkus B; Marsden D; Merritt Ii JL
Orphanet J Rare Dis; 2024 May; 19(1):189. PubMed ID: 38715031
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII.
Derrick-Roberts AL; Pyragius CE; Kaidonis XM; Jackson MR; Anson DS; Byers S
Hum Gene Ther; 2014 Sep; 25(9):798-810. PubMed ID: 25003807
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy.
Vogler C; Levy B; Galvin NJ; Thorpe C; Sands MS; Barker JE; Baty J; Birkenmeier EH; Sly WS
Pediatr Res; 1999 Jun; 45(6):838-44. PubMed ID: 10367775
[TBL] [Abstract][Full Text] [Related]
9. Vestronidase Alfa: A Review in Mucopolysaccharidosis VII.
McCafferty EH; Scott LJ
BioDrugs; 2019 Apr; 33(2):233-240. PubMed ID: 30848434
[TBL] [Abstract][Full Text] [Related]
10. Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans.
de Ru MH; van der Tol L; van Vlies N; Bigger BW; Hollak CE; Ijlst L; Kulik W; van Lenthe H; Saif MA; Wagemans T; van der Wal WM; Wanders RJ; Wijburg FA
J Inherit Metab Dis; 2013 Mar; 36(2):247-55. PubMed ID: 22991166
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival.
Vogler C; Sands MS; Levy B; Galvin N; Birkenmeier EH; Sly WS
Pediatr Res; 1996 Jun; 39(6):1050-4. PubMed ID: 8725268
[TBL] [Abstract][Full Text] [Related]
12. First Report of a Patient with MPS Type VII, Due to Novel Mutations in
Dubot P; Sabourdy F; Plat G; Jubert C; Cancès C; Broué P; Touati G; Levade T
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661765
[TBL] [Abstract][Full Text] [Related]
13. Missense models [Gustm(E536A)Sly, Gustm(E536Q)Sly, and Gustm(L175F)Sly] of murine mucopolysaccharidosis type VII produced by targeted mutagenesis.
Tomatsu S; Orii KO; Vogler C; Grubb JH; Snella EM; Gutierrez MA; Dieter T; Sukegawa K; Orii T; Kondo N; Sly WS
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14982-7. PubMed ID: 12403825
[TBL] [Abstract][Full Text] [Related]
14. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease.
Vogler C; Sands MS; Galvin N; Levy B; Thorpe C; Barker J; Sly WS
J Inherit Metab Dis; 1998 Aug; 21(5):575-86. PubMed ID: 9728337
[TBL] [Abstract][Full Text] [Related]
15. Numerous transcriptional alterations in liver persist after short-term enzyme-replacement therapy in a murine model of mucopolysaccharidosis type VII.
Woloszynek JC; Roberts M; Coleman T; Vogler C; Sly W; Semenkovich CF; Sands MS
Biochem J; 2004 Apr; 379(Pt 2):461-9. PubMed ID: 14705966
[TBL] [Abstract][Full Text] [Related]
16. Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice.
Montaño AM; Oikawa H; Tomatsu S; Nishioka T; Vogler C; Gutierrez MA; Oguma T; Tan Y; Grubb JH; Dung VC; Ohashi A; Miyamoto K; Orii T; Yoneda Y; Sly WS
Mol Genet Metab; 2008 Jun; 94(2):178-89. PubMed ID: 18359257
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function.
O'Connor LH; Erway LC; Vogler CA; Sly WS; Nicholes A; Grubb J; Holmberg SW; Levy B; Sands MS
J Clin Invest; 1998 Apr; 101(7):1394-400. PubMed ID: 9525982
[TBL] [Abstract][Full Text] [Related]
18. Oral manifestations in patients and dogs with mucopolysaccharidosis Type VII.
Kantaputra PN; Smith LJ; Casal ML; Kuptanon C; Chang YC; Nampoothiri S; Paiyarom A; Veerasakulwong T; Trachoo O; Ketudat Cairns JR; Chinadet W; Tanpaiboon P
Am J Med Genet A; 2019 Mar; 179(3):486-493. PubMed ID: 30653816
[TBL] [Abstract][Full Text] [Related]
19. Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII.
Huynh HT; Grubb JH; Vogler C; Sly WS
Proc Natl Acad Sci U S A; 2012 Oct; 109(42):17022-7. PubMed ID: 23027951
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy improves reproductive performance in mucopolysaccharidosis type VII mice but does not prevent postnatal losses.
Soper BW; Pung AW; Vogler CA; Grubb JH; Sly WS; Barker JE
Pediatr Res; 1999 Feb; 45(2):180-6. PubMed ID: 10022587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
